首页 | 官方网站   微博 | 高级检索  
     


HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
Authors:Curtis R Pickering PhD  Mitchell J Frederick PhD  Genevieve A Andrews MD  Samar A Jasser PhD  David R Fooshee BS  Zvonimir L Milas MD  Chad Galer MD  Daisuke Sano MD  PhD  William N William MD Jr  Edward Kim MD  John Heymach MD  PhD  Lauren A Byers MD  Vali Papadimitrakopoulou MD  Jeffrey N Myers MD  PhD
Affiliation:1. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Division of Otolaryngology – Head and Neck Surgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania;3. Institute for Genomics and Bioinformatics, Department of Information and Computer Sciences, University of California, Irvine, Irvine, California;4. Department of Head and Neck Surgical Oncology, MD Anderson Cancer Center Orlando, Orlando, Florida;5. Richard L Roudebush VAMC/Department of Otolaryngology‐Head and Neck Surgery, Indiana University, Indianapolis, Indiana;6. Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan;7. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Abstract:
Keywords:epidermal growth factor receptor  erlotinib  HRAS  resistance  head and neck squamous cell carcinoma
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号